<DOC>
	<DOC>NCT02557646</DOC>
	<brief_summary>The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic response (SVR) in participants who have been receiving combination therapy with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus).</brief_summary>
	<brief_title>An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants with serologically confirmed chronic hepatitis C Participants using and accepting a double method of contraception Participants not approved by the national treatment guideline or the Interferon Committee for combined pegylated interferonribavirin treatment Contraindications in the summary of product characteristics of pegylated interferon alpha2a and ribavirin Participants previously treated with pegylated interferon and/or ribavirin Hepatitis B and Human Immunodeficiency Virus coinfections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>